Sort
17,828 grants matching “crispr”
Mechanisms of Hedgehog signaling in glioblastoma
$537,026David R Raleigh · University Of California, San Francisco · R01 · FY2025 · CA
Developmentally Regulated Enhancers and Chromatin Architecture in Human Neurogenesis
$537,026Dimitris G. Placantonakis · New York University School Of Medicine · R01 · FY2023 · NS
Optimization of low-threshold Cas9-based gene drive systems to introduce Zika virus resistance in Aedes aegypti
$537,024Alexander William Eduard Franz · University Of Missouri-Columbia · R56 · FY2022 · AI
Vascular autophagy as a mediator of vascular aging and homeostasis
$536,994Toren Finkel · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · HL
Evaluation of genetic variants affecting platelet function with CRISPR HDR in human megakaryocytes
$536,992Jesse Rowley · Utah State Higher Education System--University Of Utah · R01 · FY2025 · HL
Evaluation of genetic variants affecting platelet function with CRISPR HDR in human megakaryocytes
$536,992Jesse Rowley · University Of Utah · R01 · FY2023 · HL
Disabling the replication-competent HIV provirus in the reservoir by combined CRISPR-Cas action
$536,971Benjamin Berkhout · Academical Medical Center · R01 · FY2022 · AI
Engineering Human Heart Tissues with Polyploid Cardiomyocytes
$536,797Nenad Bursac · Duke University · R01 · FY2024 · HL
Functional and Therapeutic Significance of PLK4 in Melanoma
$536,631Nihal Ahmad · University Of Wisconsin-Madison · R01 · FY2023 · CA
Editing of the AAT locus using novel base editing and prime editing technologies
$536,581Wen Xue · Univ Of Massachusetts Med Sch Worcester · P01 · FY2024 · HL
Modulation of Immune responses to gene therapy by Creation of AAV-specific Chimeric antigen receptor regulatory T cells (CAR-Tregs)
$536,581Allison May Keeler-Klunk · Univ Of Massachusetts Med Sch Worcester · P01 · FY2024 · HL
Mechanisms of cell proliferation in whole-genome doubled cells
$536,499Neil J. Ganem · Boston University Medical Campus · R01 · FY2023 · CA
RNA-Binding Proteins as Molecular Integrators that Control the Response of HGSOC to Ant-Cancer Therapies
$536,497Michael B Yaffe · Massachusetts Institute Of Technology · R01 · FY2020 · CA
RNA-Binding Proteins as Molecular Integrators that Control the Response of HGSOC to Ant-Cancer Therapies
$536,497Michael B Yaffe · Massachusetts Institute Of Technology · R01 · FY2022 · CA
RNA-Binding Proteins as Molecular Integrators that Control the Response of HGSOC to Ant-Cancer Therapies
$536,497Michael B Yaffe · Massachusetts Institute Of Technology · R01 · FY2021 · CA
RNA-Binding Proteins as Molecular Integrators that Control the Response of HGSOC to Ant-Cancer Therapies
$536,497Michael B Yaffe · Massachusetts Institute Of Technology · R01 · FY2019 · CA
Programmed Cell Death In The Nervous System
$536,363Richard Youle · National Institute Of Neurological Disorders And Stroke · ZIA · FY2023 · NS
Project 4: Transcriptional Coactivators and Enhancers in Human Cancer
$536,356Christopher Vakoc · Cold Spring Harbor Laboratory · P01 · FY2019 · CA
DEVELOPMENT OF AAV-CRISPR/CAS9-BASED THERAPIES FOR CONE ROD DYSTROPHY
$536,347Shannon Elizabeth Boye · University Of Florida · R01 · FY2021 · EY
Development of Technologies for Efficient In Vivo Prime Editing
$536,345Pablo Perez-Pinera · University Of Illinois At Urbana-Champaign · R01 · FY2024 · GM
Development of Technologies for Efficient In Vivo Prime Editing
$536,345Pablo Perez-Pinera · University Of Illinois At Urbana-Champaign · R01 · FY2022 · GM
Development of Technologies for Efficient In Vivo Prime Editing
$536,345Pablo Perez-Pinera · University Of Illinois At Urbana-Champaign · R01 · FY2023 · GM
Deciphering the molecular control of intratumoral dendritic cells
$536,319Miriam Merad · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · CA
Deciphering the molecular control of intratumoral dendritic cells
$536,319Miriam Merad · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · CA
Development and characterization of mouse models of RP59 DHDDS deficiency
$536,290Steven J Pittler · University Of Alabama At Birmingham · R01 · FY2021 · EY